Meropenem for Complicated Bacterial Infections

Indications and Usage

• The Surgical Infection Society recommends meropenem as effective monotherapy for complicated intra-abdominal infections 1
• Meropenem is used in the treatment of necrotizing infections of skin, fascia, and muscle requiring broad-spectrum coverage 2

Dosing and Administration

• For carbapenem-resistant Enterobacteriaceae (CRE) infections, the guideline recommends 1 gram IV every 8 hours by extended infusion (3 hours) in combination therapy 1
• Extended infusion (3 hours) is recommended for CRE infections or when meropenem MIC ≥8 mg/L 1

Treatment Duration and Monitoring

• The treatment duration for complicated intra-abdominal infections typically lasts 5-7 days, individualized based on infection site, source control, and clinical response 1
• The Society of Critical Care Medicine suggests prolonged or continuous infusions for critically ill patients with healthcare-associated infections 1

Clinical Considerations

• For CRE infections, combination therapy is recommended 1

Meropenem Prolonged Infusion Guidelines

Indications for Prolonged Infusion

• The Infectious Diseases Society of America recommends meropenem prolonged infusion for 3 hours, especially for carbapenem-resistant Enterobacteriaceae (CRE) infections or bacterial infections with a minimum inhibitory concentration (MIC) value ≥8 mg/L 3, 4
• In critically ill patients, particularly those with healthcare-associated infections, prolonged infusion is preferred to achieve pharmacodynamic targets 5

Dosage and Administration

• For CRE infections, 1 gram IV every 8 hours, with a 3-hour prolonged infusion, is recommended as part of combination therapy 3
• For high MIC value (≥16 mg/L) KPC-producing K. pneumoniae infections, 2 grams IV every 8 hours, with a 3-hour prolonged infusion, is recommended 3

Meropenem Therapy for Resistant Infections

Clinical Indications and Treatment

• Meropenem-vaborbactam is recommended for carbapenem-resistant Enterobacteriaceae (CRE) bloodstream infections, as per the guidelines, for effective treatment of serious infections 6
• The use of meropenem in combination with colistin is recommended for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, providing a valuable treatment option for resistant infections 7
• Meropenem is effective against methicillin-susceptible Staphylococcus aureus, making it a suitable choice for treating infections caused by this organism, as supported by the guidelines 8

Combination Therapy

• Combination therapy, such as meropenem with colistin, may be beneficial in severely ill patients with carbapenem-resistant infections, highlighting the importance of combination therapy in treating resistant infections 8

Meropenem Administration Guidelines

Standard Dosing

• Meropenem does not require a loading dose for standard administration in patients with normal renal function 9
• For carbapenem-resistant Acinetobacter baumannii infections, Meropenem 2 g IV every 8 hours is recommended without any loading dose 10
• For general severe infections in ICU patients, the standard regimen is meropenem 2 g every 8 hours with no loading dose specified 9

Contrast With Other Antibiotics

• Colistin requires a loading dose of 5 mg CBA/kg IV before maintenance dosing 10
• Tigecycline requires a loading dose of 100 mg IV before 50 mg every 12 hours 10
• Vancomycin benefits from loading doses of 35 mg/kg for rapid target attainment 11

Optimization Strategies

• Extended infusion over 3 hours is recommended for specific situations, such as when MIC ≥8 mg/L, to optimize pharmacodynamic targets 10
• The key to meropenem optimization is not a loading dose, but rather ensuring adequate time above MIC through extended infusion when treating resistant organisms or critically ill patients 11

Meropenem Dosing Recommendations

Standard Dosing

• The standard regimen for meropenem therapy is 1 gram IV every 8 hours or 2 grams IV every 8 hours, depending on infection severity and pathogen susceptibility, with no loading dose specified, as recommended by the World Journal of Emergency Surgery guidelines 12
• For critically ill patients with healthcare-associated intra-abdominal infections, guidelines recommend meropenem 1 gram every 8 hours without any loading dose, as per the World Journal of Emergency Surgery guidelines 12

Optimization Strategy

• Extended infusion over 3 hours is recommended when treating resistant organisms with MIC ≥8 mg/L or for carbapenem-resistant Enterobacteriaceae infections, as suggested by the Clinical Microbiology and Infection guidelines 13

Meropenem Therapy for Resistant Infections

Introduction to Meropenem Therapy

• The Infectious Diseases Society of America recommends meropenem-vaborbactam 4 grams IV every 8 hours for KPC-producing CRE infections when susceptible 14
• The European Society of Clinical Microbiology and Infectious Diseases suggests considering high-dose extended-infusion meropenem as part of combination therapy with two in vitro active agents for CRAB with meropenem MIC ≤8 mg/L 15

Treatment of Resistant Organisms

• The Clinical Infectious Diseases journal reports that meropenem is not effective against MRSA (methicillin-resistant S. aureus) and VRE (vancomycin-resistant enterococci) 16
• The Surgical Infection Society guidelines recommend meropenem as effective monotherapy for complicated intra-abdominal infections 17

Duration of Treatment

• The Clinical Infectious Diseases journal suggests treating complicated intra-abdominal infections for 5-7 days, individualized based on source control adequacy and clinical response, and discontinuing within 24 hours if no infection beyond gallbladder wall for cholecystitis with cholecystectomy 17

Meropenem Prolonged Infusion Duration

Introduction to Prolonged Infusion

• The Intensive Care Medicine society recommends that beta-lactam antibiotics, such as meropenem, should have plasma concentrations above the MIC for at least 70% of the time 18
• A higher target (Cmin/MIC >4-6) increases the success rate in critically ill patients, according to the Intensive Care Medicine guidelines 18
• In cases of deep infection foci, major pharmacokinetic changes, or high MIC risk, continuous infusion should be considered, as suggested by the Intensive Care Medicine journal 18
• Meropenem is an unstable antibiotic, and stability issues may occur during continuous infusion, as noted in the Intensive Care Medicine journal 18
• Very low concentrations can lead to inadequate efficacy in the infection site, according to the Intensive Care Medicine guidelines 18

Antibiotic Treatment for Carbapenem-Susceptible, Multidrug-Resistant Gram-Negative Infections

Infection Site-Specific Recommendations

• The Infectious Diseases Society of America recommends meropenem 1 gram IV every 8 hours by extended infusion for bloodstream infections or sepsis, with treatment duration of 7-14 days depending on source control and clinical response 19, 20, 21
• For complicated urinary tract infections, the European Society of Clinical Microbiology and Infectious Diseases suggests either ertapenem 1 gram IV daily or meropenem 1 gram IV every 8 hours as first-line options, with treatment duration of 5-7 days 19, 20
• Meropenem 1 gram IV every 8 hours is preferred for complicated intra-abdominal infections, providing superior anaerobic coverage compared to ertapenem 19, 20, 22
• The American Thoracic Society recommends meropenem 2 grams IV every 8 hours by extended infusion for pneumonia, with treatment duration of at least 7 days 21, 23

Critical Dosing Considerations

• The American College of Clinical Pharmacy recommends standard dose of meropenem as 1 gram IV every 8 hours for most infections, and high-dose regimen of 2 grams IV every 8 hours for severe infections or pneumonia 19, 20, 21
• Extended infusion over 3 hours is recommended to maximize time above MIC, particularly for critically ill patients 19, 20, 21
• Gentamicin dosing is recommended as 5-7 mg/kg/day IV once daily, with monitoring of trough levels and renal function 19, 20, 24

Antibiotic Stewardship Considerations

• The Society for Healthcare Epidemiology of America recommends that de-escalation is not appropriate given the organism's extensive resistance pattern, and carbapenem use is justified as no narrower-spectrum alternatives are available 19, 20, 25
• Obtaining infectious disease consultation is recommended for recurrent infections or treatment failures 19, 20
• Repeat susceptibility testing is recommended if clinical failure occurs, as resistance can emerge during therapy 25

Maximum Duration of Meropenem Therapy

Standard Treatment Durations by Infection Type

• The Infectious Diseases Society of America recommends treatment of meningococcal sepsis with meropenem for 5 days in patients who have recovered 26
• The Infectious Diseases Society of America recommends treatment of pneumococcal meningitis with meropenem for 10 days if stable, up to 14 days if taking longer to respond 26
• The Infectious Diseases Society of America recommends treatment of Haemophilus influenzae meningitis with meropenem for 10 days 26
• The Infectious Diseases Society of America recommends treatment of Enterobacteriaceae meningitis with meropenem for 21 days 26
• The Infectious Diseases Society of America recommends treatment of Listeria monocytogenes meningitis with meropenem for 21 days 26
• The Infectious Diseases Society of America recommends treatment of Burkholderia pseudomallei (melioidosis) with meropenem for 14 days intensive phase, followed by prolonged eradication phase; 4-8 weeks or longer if critically ill, extensive pulmonary disease, deep-seated collections, organ abscesses, osteomyelitis, septic arthritis, or neurologic involvement 27

Key Considerations for Extended Therapy

• The American College of Clinical Pharmacy and the Infectious Diseases Society of America suggest that treatment should be extended when patient is not responding to therapy within the standard timeframe, deep-seated infections or organ abscesses are present, inadequate source control has been achieved, critically ill patients with extensive disease, central nervous system involvement, or osteomyelitis or septic arthritis are present 26, 27
• The Infectious Diseases Society of America recommends against discontinuing therapy at 14 days if clinical response is incomplete or infection characteristics warrant longer treatment 26, 27
• The Infectious Diseases Society of America recommends against stopping meropenem before 21 days for meningitis caused by Enterobacteriaceae or Listeria, as it risks treatment failure 26

Meropenem Adult Dosing Guidelines

Standard Dosing by Infection Type

• The Infectious Diseases Society of America recommends administering meropenem 1 gram IV every 8 hours as part of combination therapy for necrotizing infections 28, 29
• For community-acquired intra-abdominal infections in non-critically ill patients, the World Journal of Emergency Surgery suggests a dose of 1 gram IV every 8 hours 30
• In cases of healthcare-associated intra-abdominal infections in critically ill patients, consider a dose of 1 gram IV every 8 hours with extended infusion 30

Hospital-Acquired and Ventilator-Associated Pneumonia

• For low risk of multidrug-resistant organisms, the Journal of Microbiology, Immunology and Infection recommends 1 gram IV every 8 hours 31
• In high risk of multidrug-resistant organisms, the Journal of Microbiology, Immunology and Infection suggests 1 gram IV every 8 hours as part of combination therapy 31

Meropenem Dosing for Central Nervous System Infections

Dosing Recommendations

• The Infectious Diseases Society of America recommends 2 grams IV every 8 hours for meningitis caused by Enterobacteriaceae or suspected ESBL organisms 32, 33, 34

Meropenem Prolonged Infusion for MDR Proteus mirabilis

Rationale for Prolonged Infusion

• The Infectious Diseases Society recommends prolonged infusion of β-lactams for pathogens with high minimum inhibitory concentration (MIC) (Strong recommendation, low quality of evidence) 35, 36

Clinical Considerations for MDR Proteus mirabilis

• Tigecycline lacks in vitro activity against P. mirabilis, making meropenem a superior choice for this pathogen 37
• Infectious disease consultation is highly recommended in the management of infections caused by multidrug-resistant organisms (Strong recommendation, low quality of evidence) 35, 36
• Antimicrobial susceptibility testing should guide final antibiotic selection and allow for potential de-escalation 35, 36

Step-Down Therapy Options for Meropenem

General Principles of De-escalation

• Clinical stability criteria include temperature ≤37.8°C, heart rate ≤100 beats/min, respiratory rate ≤24 breaths/min, systolic blood pressure ≥90 mmHg, oxygen saturation ≥90%, ability to maintain oral intake, and normal mental status 38, 39, 40

Pathogen-Specific Step-Down Options

• For Enterobacteriaceae (susceptible strains), step down to oral fluoroquinolones (ciprofloxacin 500-750 mg twice daily or levofloxacin 750 mg daily) for susceptible Gram-negative organisms 41
• For Enterobacteriaceae (susceptible strains), ertapenem 1 gram IV daily can be used as an intermediate step for complicated infections requiring continued parenteral therapy but allowing once-daily dosing 38, 39
• For Pseudomonas aeruginosa, de-escalate from combination to monotherapy once susceptibility is confirmed 38, 40
• For Pseudomonas aeruginosa, continue with an antipseudomonal agent (oral ciprofloxacin 750 mg twice daily if susceptible) 41
• For Melioidosis (Burkholderia pseudomallei), a mandatory two-phase approach is required, including an intensive phase with meropenem, ceftazidime, or imipenem for a minimum of 14 days, and an eradication phase with trimethoprim-sulfamethoxazole for 3-6 months to prevent relapse 38, 39, 40
• For Mixed Intra-Abdominal Infections, oral amoxicillin-clavulanate can be used for susceptible organisms once clinical stability is achieved 38, 39
• For Mixed Intra-Abdominal Infections, oral fluoroquinolones plus metronidazole can be used for Gram-negative coverage with anaerobic activity 41

Timing of Step-Down

• Initiate step-down after 48 hours of clinical stability for most infections, with a total course of 5-7 days for mild-to-moderate community-acquired pneumonia, and 7-day total course for severe community-acquired pneumonia 38, 39, 40

Critical Pitfalls to Avoid

• Do not attempt step-down in scenarios with persistent clinical instability, such as fever, hemodynamic instability, or worsening organ dysfunction 38, 39

Special Populations Requiring Extended Therapy

• Critically ill patients with extensive disease require continued therapy until substantial clinical improvement 38, 39, 40

Meropenem IV Dosing and Management for Severe Cellulitis with Necrotic Tissue

Dosing Regimen

• Standard regimen: Meropenem 1 g IV every 8 hours (30‑minute infusion) as part of mandatory broad‑spectrum combination therapy for severe cellulitis with necrotic tissue, administered for 7–14 days based on clinical response and adequacy of surgical debridement. 42
• High‑dose option for suspected necrotizing infection or systemic toxicity: Meropenem 2 g IV every 8 hours (consider extended infusion in critically ill patients). 42

Combination Therapy

• Mandatory MRSA coverage: Meropenem alone lacks activity against MRSA; therefore, concurrent therapy with either vancomycin (15–20 mg/kg IV every 8–12 hours) or linezolid (600 mg IV twice daily) is required. 42
• Alternative carbapenem‑sparing regimen: Piperacillin‑tazobactam 3.375–4.5 g IV every 6 hours can replace meropenem when carbapenem sparing is desired. 42

Treatment Duration

• Standard duration: 7–10 days of IV therapy for severe cellulitis with necrotic tissue that has undergone surgical debridement, with reassessment at day 5 to decide on extension. 42
• Extended duration indications: 10–14 days when source control is inadequate, systemic toxicity persists, or tissue involvement is extensive; therapy continues until fever resolves, white‑blood‑cell count normalizes, and wound healing progresses. 42

Surgical Management

• Urgent surgical consultation: Prompt surgical evaluation within 1 hour is mandatory for suspected necrotizing fasciitis or gas gangrene; debridement is the primary treatment, with antibiotics serving as adjunctive therapy. 42
• Warning signs that mandate immediate surgery:

Transition to Oral Therapy

• Criteria for oral switch: All necrotic tissue must be debrided, systemic toxicity resolved, and the wound must show granulation tissue before transitioning. 42
• Oral regimens after stabilization (afebrile > 48 h, improving wound, tolerating oral intake):
• Total course length (IV + oral): 10–14 days. 42

Clinical Pitfalls to Avoid

• Do not use meropenem monotherapy for necrotizing infections; MRSA coverage is mandatory. 42
• Avoid under‑dosing in patients receiving renal replacement therapy (e.g., CRRT) because significant drug removal occurs, necessitating higher doses than those predicted by creatinine clearance alone. 42
• Do not delay surgical debridement while awaiting antibiotic effect; delayed surgery markedly increases mortality. 42
• Do not stop antibiotics at 5 days for necrotizing infections; the 5‑day rule applies only to uncomplicated cellulitis. 42
• Do not rely solely on creatinine‑clearance formulas for dosing in critically ill or obese patients; therapeutic drug monitoring should be considered. 42

Pharmacodynamic Differences Between Aminoglycosides and Meropenem

Aminoglycoside Dosing in Cystic Fibrosis

• In cystic fibrosis patients, once‑daily dosing of tobramycin or amikacin results in higher airway concentrations compared with multiple daily doses, supporting the use of a single daily administration schedule. 43

Mechanistic Contrast Between Drug Classes

• Aminoglycosides exhibit concentration‑dependent killing and possess a prolonged post‑antibiotic effect, whereas meropenem demonstrates time‑dependent killing without a significant post‑antibiotic effect. This fundamental pharmacodynamic difference explains why dosing strategies appropriate for aminoglycosides are not applicable to meropenem. 43

Clinical Implication for Meropenem Dosing

• The pharmacodynamic principles that justify once‑daily dosing of aminoglycosides do not apply to meropenem; therefore, meropenem should be administered at intervals that maintain plasma concentrations above the pathogen’s MIC for the required proportion of the dosing interval (typically every 8 hours). 43

Duration of Meropenem Therapy by Infection Type

Community‑Acquired Pneumonia (CAP)

• Mild‑to‑moderate CAP – 5–7 days of meropenem is recommended when the patient has been afebrile for ≥48 hours and meets clinical stability criteria (temperature ≤ 37.8 °C, heart rate ≤ 100 bpm, respiratory rate ≤ 24 breaths/min, systolic BP ≥ 90 mmHg, oxygen saturation ≥ 90 %, able to maintain oral intake, normal mental status)【44】.
• Severe CAP – a fixed 7‑day course is advised for high‑severity presentations【44】.

Intra‑Abdominal Infections

• Complicated intra‑abdominal infections with adequate source control and favorable clinical response – 5–7 days of meropenem is sufficient【45】.
• Extension of therapy – treatment should be prolonged when deep‑seated infections or organ abscesses are present, or when source control is inadequate【45】.

Meningitis (Pathogen‑Specific Durations)

• Meningococcal meningitis – 5 days of meropenem in patients who have clinically recovered【46】.
• Pneumococcal meningitis – 10 days if the patient is stable; up to 14 days if the response is slower【46】.
• Enterobacteriaceae meningitis – 21 days of therapy is required【46】.

Melioidosis (Burkholderia pseudomallei)

• Intensive phase – at least 14 days of meropenem, followed by a mandatory prolonged eradication phase【44】.
• Critically ill or extensive disease – total intensive‑phase duration of 4–8 weeks or longer (e.g., extensive pulmonary disease, deep‑seated collections, organ abscesses, osteomyelitis, septic arthritis, neurologic involvement)【44】.
• Eradication phase – 3–6 months of oral trimethoprim‑sulfamethoxazole to prevent relapse【44】.

Criteria for Extending Meropenem Therapy

• Presence of deep‑seated infections or organ abscesses warrants extension beyond standard durations【45】.
• Inadequate source control (e.g., incomplete drainage) also necessitates prolonged therapy【45】.
• Central nervous system involvement requires longer courses (e.g., meningitis)【46】.
• Osteomyelitis or septic arthritis similarly call for extended treatment【45】.

Oral Switch Criteria

• Resolution of systemic toxicity – required before transitioning to oral agents【45】.
• Afebrile for >48 hours – a prerequisite for oral step‑down【44】.
• Wound granulation tissue – indicates readiness for oral therapy in skin/soft‑tissue infections【44】.

Oral Step‑Down Options After Meropenem

• Amoxicillin‑clavulanate 875/125 mg twice daily for susceptible organisms【44】.
• Levofloxacin 750 mg daily plus metronidazole 500 mg three times daily for patients allergic to penicillins【44】.
• Ciprofloxacin 500–750 mg twice daily for susceptible Gram‑negative pathogens【44】.
• Melioidosis exception – oral trimethoprim‑sulfamethoxazole for 3–6 months is mandatory after the intensive phase to prevent relapse【44】.

Meropenem: Lack of Oral Formulation and Clinical Implications

Administration Routes Confirmed by Guidelines

• Clinical practice guidelines from infectious disease societies specify that meropenem is administered exclusively by intravenous infusion (standard or extended), intravenous bolus, or intramuscular injection; no oral formulation is included in any treatment protocol. 47, 48, 49

Antibiotic Stewardship and IV‑to‑Oral Conversion

• Antibiotic stewardship programs identify meropenem as an agent without an oral equivalent, requiring infectious‑disease specialist consultation before any switch from intravenous therapy, rather than allowing automatic IV‑to‑oral conversion. 47

Research Gaps and Unmet Needs in Tuberculosis Treatment

• Tuberculosis treatment guidelines highlight the unmet need for oral carbapenems; meropenem demonstrates activity against drug‑resistant Mycobacterium tuberculosis but its requirement for chronic parenteral administration limits practicality in resource‑limited settings. 48, 49

Y‑Site Co‑Administration of Meropenem with Clindamycin and Gentamicin

Broad‑Spectrum Coverage with MRSA Activity

• Meropenem can be administered together with clindamycin through the same intravenous line, providing combined Gram‑negative/anaerobic coverage and MRSA activity without the need for separate vascular access. 50

Necrotizing Skin and Soft‑Tissue Infections

• In severe skin and soft‑tissue infections, a regimen of meropenem (1–2 g IV every 8 hours) plus clindamycin (600 mg IV every 8 hours) may be infused simultaneously via a Y‑site, delivering both broad‑spectrum and anti‑MRSA therapy. 50

Prosthetic Valve Endocarditis (MRSA)

• For MRSA prosthetic valve endocarditis, the guideline‑recommended combination of vancomycin, gentamicin, and rifampin can be theoretically modified by substituting meropenem for vancomycin; gentamicin remains Y‑site compatible with meropenem in this scenario. 50

Practical Line Management for Clindamycin

• A clindamycin dose of 600 mg IV every 8 hours (infused over 30–60 minutes) can be scheduled to overlap with meropenem infusions, eliminating the need for line flushing or interruption. 50

Evidence‑Based Meropenem Dosing and Alternative Regimens

Adult Indication‑Specific Dosing

• Complicated intra‑abdominal infections – Administer meropenem 1 g intravenously every 8 hours as a 30‑minute infusion. This regimen is supported by clinical data. 51
• Bacterial meningitis caused by Enterobacterales or ESBL organisms – Use meropenem 2 g intravenously every 8 hours (30‑minute infusion). Recommended for central nervous system infections with resistant Gram‑negative pathogens. 52
• Pneumococcal meningitis with high‑level resistance – Treat with meropenem 2 g intravenously every 8 hours. Evidence indicates this dose achieves adequate cerebrospinal fluid concentrations. 52

Pediatric Dosing

• Complicated intra‑abdominal infections in children – Give meropenem 60 mg/kg per day divided every 8 hours (maximum 6 g/day). Pediatric dosing aligns with adult efficacy data. 51
• Standard pediatric dosing for most infections – Meropenem 20 mg/kg intravenously every 8 hours. This dose provides appropriate exposure in the pediatric population. 51
• Pediatric meningitis – Administer meropenem 40 mg/kg intravenously every 8 hours (maximum 2 g per dose). This higher dose is recommended for central nervous system infections to ensure adequate CSF levels. [51][52]
• Neonates with necrotizing enterocolitis – Include meropenem as part of a broad‑spectrum regimen together with ampicillin and metronidazole. Combination therapy is advised for severe neonatal gastrointestinal infection. 51

Treatment Duration for Specific Infections

• Complicated intra‑abdominal infections with adequate source control – Limit therapy to 5–7 days. Short‑course treatment is sufficient when infection focus is controlled. 51
• Acute cholecystitis after cholecystectomy – Discontinue meropenem within 24 hours unless infection extends beyond the gallbladder wall. Early cessation is safe with effective surgical source control. 51

Alternative Antimicrobial Regimens (When Meropenem Cannot Be Used)

• Patients with non‑severe β‑lactam allergy – Replace meropenem with aztreonam plus metronidazole to cover Gram‑negative and anaerobic organisms. Evidence supports comparable efficacy. 51
• Patients with non‑severe β‑lactam allergy (alternative) – Use a fluoroquinolone (ciprofloxacin or levofloxacin) combined with metronidazole. This regimen provides broad‑spectrum coverage. 51
• Severe β‑lactam allergy – Employ an aminoglycoside (gentamicin or tobramycin) plus metronidazole for Gram‑negative and anaerobic coverage. Clinical data endorse this combination. 51
• Severe β‑lactam allergy with need for Gram‑positive coverage – Combine aztreonam, metronidazole, and vancomycin to achieve comprehensive antimicrobial activity. Supported by infection‑control studies. 51
• Carbapenem‑sparing option for susceptible organisms – Use cefepime 2 g intravenously every 8 hours. This fourth‑generation cephalosporin is an effective alternative when meropenem is unavailable. 51
• Meningitis when meropenem is unavailable – Administer ceftriaxone 2 g intravenously every 12 hours or cefotaxime 2 g intravenously every 4–6 hours. These agents are validated for bacterial meningitis. 52
• Pneumococcal meningitis with penicillin/cephalosporin resistance – Add vancomycin to the ceftriaxone or cefotaxime regimen to ensure activity against resistant Streptococcus pneumoniae. Evidence supports this combination. 52

Meropenem as Preferred Monotherapy for Complicated Intra‑Abdominal Infections in Patients with Renal Impairment

Guideline Recommendations

• The Surgical Infection Society and the Infectious Diseases Society of America explicitly recommend meropenem as effective monotherapy for complicated intra‑abdominal infections, whereas cefepime requires addition of metronidazole to achieve adequate anaerobic coverage. 53, 54
• Both the 2010 IDSA/SIS guidelines and the 2003 IDSA guidelines list meropenem as a first‑line single‑agent option for complicated intra‑abdominal infections, while cefepime is mentioned only in combination regimens. 53, 54
• Meropenem can replace cefepime for presumed intra‑abdominal infections in adults with impaired renal function and is preferred over cefepime in current guidelines for complicated intra‑abdominal infections. 53, 54

Treatment Duration

• A course of 5–7 days of meropenem is sufficient for complicated intra‑abdominal infections when adequate source control (surgical drainage or resection) has been achieved and the patient shows clinical response (afebrile > 48 h, normalizing white‑blood‑cell count, return of gastrointestinal function). 53
• Therapy should be extended beyond 7 days only if source control is inadequate or delayed, if deep‑seated infections or organ abscesses are present, or if the patient remains critically ill with persistent systemic toxicity. 53

Safety and Stewardship

• Meropenem should not be continued after resolution of clinical signs of infection, because prolonged therapy increases the risk of Clostridioides difficile colitis, superinfection, and antimicrobial resistance. 53

Meropenem Standard Dosing and Duration for Complicated Intra‑Abdominal Infections

Standard Dosing Recommendations

• In adults with normal renal function, the recommended regimen for complicated intra‑abdominal infections is meropenem 1 g administered intravenously every 8 hours; this dosing is supported by evidence from the World Journal of Emergency Surgery (2020) 55.

Recommended Treatment Duration

• Antibiotic therapy should be stopped once clinical resolution is achieved (afebrile ≥ 48 h, normalized white‑blood‑cell count, and resolution of ileus); extending therapy beyond this point increases the risk of Clostridioides difficile infection and antimicrobial resistance, as reported in the World Journal of Emergency Surgery (2020) 55.